FDA confirms rejection of Y-mabs cancer drug
The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October.
Y-mabs’ FDA application for marketing approval of its cancer candidate, 31l-omburtamab, has officially been denied in a complete response letter, in a move that shouldn’t come as a surprise to anyone.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves Ferring microbiotica-based treatment
For subscribers
